Overview
ISO/TS 21560:2020 - General requirements of tissue‑engineered medical products (TEMPs) provides high‑level, safety‑focused guidance for the quality and manufacture of tissue‑engineered medical products used in regenerative medicine. The technical specification outlines expectations for materials, manufacturing processes, characterization and control strategies, and management of unintended biological effects. It does not cover clinical trial or efficacy requirements and excludes TEMPs containing viable xenogenic cells, genetically modified cells, or cells from abnormal/cancerous tissue, as well as combinations with medical devices (except synthetic or naturally‑derived scaffolds).
Key topics and technical requirements
- Materials and starting materials: requirements and considerations for cells, tissues, scaffolds, bioactive agents, excipients and ancillary materials used during manufacturing.
- Manufacturing process: controls, process validation and contamination prevention throughout the product lifecycle.
- Characterization and control strategy: defining critical quality attributes, in‑process controls and release criteria for the finished TEMP.
- Safety and unintentional biological effects: risk reduction for adventitious agents, tumorigenicity assessment, and minimizing immunogenic or deleterious excipient reactions.
- Traceability and lifecycle control: traceability of cells, critical materials and finished products across manufacturing, storage and distribution.
- Supporting elements: container‑closure system, transport considerations, and developmental/non‑clinical studies relevant to product quality and safety.
- Risk‑based approach: recommended use of risk management (referencing ISO 13022 and related documents) to determine the extent of technical documentation and controls.
Practical applications and intended users
ISO/TS 21560:2020 is aimed at organizations and professionals involved in the development, manufacture and regulation of TEMPs, including:
- Manufacturers and quality/production teams setting up GMP‑like controls for cell‑based products and scaffolds.
- Regulatory authorities and reviewers assessing quality and safety documentation for TEMPs.
- R&D and process development groups designing characterization strategies, non‑clinical studies and validation plans.
- Suppliers of ancillary materials and biomaterials who must understand material expectations and traceability needs.
- Contract development and manufacturing organizations (CDMOs) supporting TEMP production and transport.
Related standards
- ISO 13022 - application of risk management and processing practices for cell products
- ISO/TS 20399 series - ancillary materials for cellular therapeutics
- ISO 22442 series - controls and validation for animal‑sourced materials (TSE/virus concerns)
Keywords: ISO/TS 21560:2020, tissue‑engineered medical products, TEMPs, regenerative medicine, quality control, manufacturing, risk management, scaffolds, ancillary materials, traceability.